Drug Trial Radar · NCT04060173
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
Last checked: Nov 19, 2026Latest source record: Feb 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Sep 5, 2019
Primary completion
Dec 29, 2019
Study completion Feb 7, 2020
Sponsor
- Lead sponsor
- Atom Therapeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with hyperuricemia.
Conditions
- Hyperuricemia
- Gout
Interventions
ABP-671Drug
ABP-671 is an investigational drug
PlaceboOther
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: 38 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.